08:18 AM EST, 12/17/2025 (MT Newswires) -- Nuvectis Pharma ( NVCT ) said Wednesday it has started a phase 1b study testing NXP900 in combination with osimertinib in patients with non-small cell lung cancer.

The new treatment is an oral drug candidate that stops or limits the SRX and YES1 enzymes, and the company is starting its first combination study of NXP900 within its phase 1b program.

The phase 1b program followed a phase 1a dose escalation study in advanced solid tumors and a drug interaction study in healthy volunteers, Nuvectis said.

The combination study will enroll patients with unresectable, metastatic, or locally advanced non-small cell lung cancer who previously responded to osimertinib in first or second line treatment, while excluding patients with drug resistance or certain mutations or other cancer drivers, it added.